Unknown

Dataset Information

0

Glycan engineering of the SARS-CoV-2 receptor-binding domain elicits cross-neutralizing antibodies for SARS-related viruses.

ABSTRACT: Broadly protective vaccines against SARS-related coronaviruses that may cause future outbreaks are urgently needed. The SARS-CoV-2 spike receptor-binding domain (RBD) comprises two regions, the core-RBD and the receptor-binding motif (RBM); the former is structurally conserved between SARS-CoV-2 and SARS-CoV. Here, in order to elicit humoral responses to the more conserved core-RBD, we introduced N-linked glycans onto RBM surfaces of the SARS-CoV-2 RBD and used them as immunogens in a mouse model. We found that glycan addition elicited higher proportions of the core-RBD-specific germinal center (GC) B cells and antibody responses, thereby manifesting significant neutralizing activity for SARS-CoV, SARS-CoV-2, and the bat WIV1-CoV. These results have implications for the design of SARS-like virus vaccines.

SUBMITTER: Shinnakasu R 

PROVIDER: S-EPMC8641255 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Broadly protective vaccines against SARS-related coronaviruses that may cause future outbreaks are urgently needed. The SARS-CoV-2 spike receptor-binding domain (RBD) comprises two regions, the core-RBD and the receptor-binding motif (RBM); the former is structurally conserved between SARS-CoV-2 and SARS-CoV. Here, in order to elicit humoral responses to the more conserved core-RBD, we introduced N-linked glycans onto RBM surfaces of the SARS-CoV-2 RBD and used them as immunogens in a mouse mode  ...[more]

Similar Datasets

Unknown Structures from "Engineering Neutralizing SARS-CoV Antibodies to Bind SARS-CoV-2"
| S-BSST379 | biostudies-other
Unknown SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies.
| S-EPMC7941631 | biostudies-literature
Unknown Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement.
| S-EPMC7471522 | biostudies-literature
Unknown ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants.
| S-EPMC9010245 | biostudies-literature
Unknown Glycosylated Delta-receptor-binding domain mucosal vaccine elicits broadly neutralizing antibodies with protection against SARS-CoV-2 challenge.
| S-EPMC10563057 | biostudies-literature
Genomics Potent neutralizing antibodies against SARS-CoV-2
| EGAS00001004412 | EGA
Unknown Glycan Masking of Epitopes in the NTD and RBD of the Spike Protein Elicits Broadly Neutralizing Antibodies Against SARS-CoV-2 Variants.
| S-EPMC8674692 | biostudies-literature
Unknown A Stabilized, Monomeric, Receptor Binding Domain Elicits High-Titer Neutralizing Antibodies Against All SARS-CoV-2 Variants of Concern.
| S-EPMC8695907 | biostudies-literature
Unknown Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2.
| S-EPMC7506210 | biostudies-literature
Unknown Glycan masking of hemagglutinin for adenovirus vector and recombinant protein immunizations elicits broadly neutralizing antibodies against H5N1 avian influenza viruses.
| S-EPMC3966833 | biostudies-literature